Ridgreback biotherapeutics recently reported molnupiravir's interim data after about 15-20 % of patients in their trial were treated. I expect IPIX would begin plans for an interim report at about the same time. In the Brilacidin trial 15-20% of the randomized patients will be between 30 and 40 patients.

https://www.merck.com/news/ridgeback-biothera...nupiravir/

IPIX trial describes the interim report being a safety report. So I doubt any reporting of efficacy or secondary endpoints will be reported.

" After an interim analysis safety review, by an independent Data Monitoring Committee (DMC), dosing may be extended to 5 days."

https://clinicaltrials.gov/ct2/show/NCT04784897

Nice review of Covid19 DMC responsibilities and reporting :

https://www.sciencedirect.com/science/article...329#bb0180

GLTA Farrell